CUE BIOPHARMA, INC.
40 Guest Street
Boston, Massachusetts 02135
May 24, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
| Re: | Cue Biopharma, Inc. | |
| Registration Statement on Form S-3 | ||
| Filed May 9, 2023 | ||
| File No. 333-271786 | ||
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-271786), so that it may become effective at 4:30 p.m. Eastern time on May 26, 2023, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the Staff.
| Very truly yours, | ||
| CUE BIOPHARMA, INC. | ||
| By: | /s/ Kerri-Ann Millar | |
| Name: | Kerri-Ann Millar | |
| Title: | Chief Financial Officer | |
